Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Chronic Heart Failure
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
This is a multi-center, randomized, double-blind, placebo-controlled study in subjects with stable heart failure with preserved ejection fraction (HFpEF) to evaluate the effects of 4 weeks treatment with subcutaneous MTP-131…
- Trial name
- NCT02814097
- Testing
- elamipretide
- Where
- 9 sites in Germany, Serbia
- Volunteers
- 46 people
- Sponsor
- Stealth BioTherapeutics Inc.
ANOCA - Angina With Non-obstructive Coronary Arteries, HFpEF - Heart Failure With Preserved Ejection Fraction
Peripheral Microvascular Blood Flow in ANOCA
An observational cross-sectional cohort study investigating whether peripheral endothelial function assessed using Laser speckle contrast analysis and coronary endothelial function measured with invasive coronary function testing…
- Trial name
- NCT05610410
- Testing
- Laser speckle contrast analysis
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- Amsterdam UMC, location VUmc
Dyspnea, Heart Failure With Preserved Ejection Fraction
Assessment of Pulmonary Congestion During Cardiac Hemodynamic Stress Testing
The aim of this study is to utilize lung ultrasound to detect the development of extravascular lung water in patients undergoing clinically indicated invasive hemodynamic exercise stress testing for symptomatic shortness of…
- Trial name
- NCT04019613
- Testing
- Lung ultrasound
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Type 2 Diabetes, Heart Failure
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07390110
- Testing
- Oral semaglutide, Sitagliptin
- Where
- United States
- Volunteers
- 25,664 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure With Preserved Ejection Fraction
Dapagliflozin (DAPA) Effects in HFpEF
The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and…
- Trial name
- NCT04730947
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction
Biomarkers in HF: Circulating Biomarkers of Fibrosis and Cardiovascular Disease
Heart failure with preserved ejection fraction (HFpEF) represents one of the largest unmet needs in cardiovascular medicine. Heart muscle scarring (myocardial fibrosis) is a key HFpEF disease mechanism and represents an important…
- Trial name
- NCT05826821
- Testing
- Pirfenidone
- Where
- United Kingdom
- Volunteers
- 107 people
- Sponsor
- Manchester University NHS Foundation Trust
Aortic Valve Stenosis, Heart Failure
ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
The goal of this trial is to to determine whether use of a novel SGLT2 inhibitor, Enavogliflozin 0.3 mg once daily is superior to placebo, when added to standard-of-care, in reducing the composite of major cardiovascular events…
- Trial name
- ENAVO-TAVR (NCT05672836)
- Testing
- Enavogliflozin, Standard-of-Care
- Where
- 31 sites in South Korea
- Volunteers
- 1,040 people
- Sponsor
- Duk-Woo Park, MD
Heart Failure With Preserved Ejection Fraction, Hypertension
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a critical public health problem. Heart failure (HF) affects over 5 million adults in the United States (US), and is a major source of morbidity, mortality, and impaired…
- Trial name
- BLOCK HFpEF (NCT04434664)
- Testing
- Amlodipine Besylate, Metoprolol Succinate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Heart Failure, Heart Failure With Preserved Ejection Fraction
Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program
This is a pilot randomized trial of the BAMS-HF (Balance, Aerobic capacity, Mobility and Strength in patients hospitalized for Heart Failure) Program versus usual care.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure, Systolic, Heart Failure, Diastolic
- Trial name
- BAMS-HF (NCT04281849)
- Testing
- BAMS-HF Program
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- VA Eastern Colorado Health Care System
Fontan Circulation, Single Ventricle Heart Disease
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.
- Conditions
- Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT06762964
- Testing
- Dapagliflozin tablet
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Pulmonary Hypertension
Screening and Phenotyping of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction .
Left-sided heart failure (HF) is known to cause pulmonary hypertension (PH), but the development and severity of PH in HF is highly variable, and contributing factors are not fully understood.
- Trial name
- NCT07082400
- Testing
- right heart catheter
- Volunteers
- 100 people
- Sponsor
- Sohag University
Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal)
PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF
Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL).
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal), Persistent Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- PREACTIVE (NCT07324772)
- Testing
- progressive resistance training, combined aerobic + resistance training
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
HFpEF - Heart Failure With Preserved Ejection Fraction
The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)
This study will evaluate the effect of 12 weeks of treatment with tamibarotene compared with placebo on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction…
- Trial name
- RELIEF (NCT07855692)
- Testing
- Tamibarotene
- Where
- 4 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Nagoya University
Heart Failure With Preserved Ejection Fraction (HFPEF)
The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
This project is an observational study in patients with heart failure with preserved ejection fraction (HFpEF) who are candidates for treatment with weight loss medication to manage obesity or diabetes as part of their standard…
- Trial name
- NCT06930495
- Testing
- Weight loss SOC Treatment with second generation anti-diabetic medications
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure, Diastolic
Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years)
Growing recognition of the importance of co-morbidities in Heart Failure with Preserved Ejection Fraction (HFPEF) has led to the realization that rather than being a distinct disease entity, HFPEF may represent a spectrum of…
- Trial name
- OPTIMIZE-HFPEF (NCT02425371)
- Testing
- Screening and treatment of comorbidities
- Where
- Sweden
- Volunteers
- 410 people
- Sponsor
- Göteborg University
Heart Failure With Preserved Ejection Fraction
The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF
The effectively therapeutic approaches for Heart failure with preserved ejection fraction (HFpEF) remain limited. The PARAGON-HF trial found that Angiotensin Receptor-Neprilysin Inhibition (ARNI) has potential benefits for the…
- Trial name
- ARNICFH (NCT05089539)
- Testing
- Angiotensin Receptor-Neprilysin Inhibition
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Medical University
Cardiomyopathy, Diabetic
CARdiomyopathy in Type 2 DIAbetes Mellitus
The objective of the CARDIATEAM clinical study is to assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy using unsupervised clustering approaches based on deep phenotyping (clinical…
- Trial name
- CARDIATEAM (NCT04303364)
- Where
- 17 sites in France, Germany and 3 more
- Volunteers
- 1,256 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Pulmonary Hypertension Due to Left Heart Disease, Heart Failure With Preserved Ejection Fraction
Training in HFpEF-PH
Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved…
- Trial name
- TRAIN HFpEF (NCT05464238)
- Testing
- Exercise rehabilitation, Standard treatment
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 90 people
- Sponsor
- Heidelberg University
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals